New CEO to guide TrakCel to next phase of growth
Cardiff, UK, February 17, 2020 – TrakCel, a leading software developer of orchestration systems for advanced therapies, announced today the appointment of Dr. Fiona Withey as Chief Executive Officer and co-founder Ravi Nalliah to the role of Chief Strategy Officer.
TrakCel has experienced significant growth over the last eight years, establishing itself as the best in class cellular orchestration platform for advanced therapies. Today, TrakCel supports both clinical and commercial therapies globally and multilingually with live deployments of its platform across autologous CAR-T, allogeneic CAR-T, MIL’s (Marrow Infiltrating Lymphocytes), TIL’s (Tumor Infiltrating Lymphocytes), Personalized Cancer Vaccines and Gene Edited CRISPR therapies.
Dr. Withey was previously VP Global Clinical Strategy and Managing Director UK Clinical Services at PCI Pharma Services, prior to which she was CEO of Biotec Services International, a specialist in ultra-low temperature pharma contract services.
Speaking of her appointment, Dr. Withey comments; “As a TrakCel co-founder and now as CEO I look forward to guiding TrakCel to its next phase of development to support the advanced therapies industry. TrakCel has deep industry experience, a leading product portfolio and a growing customer base. It is now critical that we drive operational excellence across the organization and deliver superior customer service to enable our customers to succeed in their therapeutic development programs.”
“TrakCel has deep industry experience, a leading product portfolio and a growing customer base. It is now critical that we drive operational excellence across the organization and deliver superior customer service to enable our customers to succeed in their therapeutic development programs.”’
As Chief Strategy Officer, Mr. Nalliah will be responsible for predicting future strategies for the sector and ensuring that TrakCel continues to innovate to meet the needs of therapeutic developers, manufacturers, caregivers and patients.
“The pace of change and development in the cell and gene therapy market is both exceptional and exciting. I have long been an advocate of moving this industry towards standardization and look forward to developing TrakCel’s product offering and ensuring that we remain at the forefront of innovation,” commented Mr. Nalliah. “Fiona will bring a combination of client focus, operational discipline and strong leadership to the team, ensuring that we continue in our crucial strategic aim of further developing our truly expert team at TrakCel. I am very proud of everything that the team has accomplished in enabling us to be the specialists in cell therapy orchestration platforms and I look forward to working with Fiona and the team to continue this success.”
TrakCel is the market leading designer, developer and deliverer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel’s software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining needle-to-needle compliance and traceability. TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey.
Article by TrakCel Marketing - 17 Feb 2020